Praxis Precision Medicines shares are trading higher after Jefferies initiated a Buy rating on the stock and announced a $4 price target.
Portfolio Pulse from Benzinga Newsdesk
Jefferies initiated a Buy rating on Praxis Precision Medicines and set a $4 price target, causing the stock to trade higher.

June 02, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Praxis Precision Medicines stock is trading higher after Jefferies initiated a Buy rating and set a $4 price target.
The Buy rating and $4 price target from Jefferies, a reputable financial firm, is a positive signal for Praxis Precision Medicines. This endorsement is likely to attract more investors and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100